A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
A phase 1/2 trial of IBI3003 in multiple myeloma, run by Innovent Biologics (Suzhou) Co. Ltd., now recruiting.
Overview
A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma is a phase 1/2 interventional study registered as NCT06083207 by Innovent Biologics (Suzhou) Co. Ltd., with 116 participants planned, started 2024-07-29 and due to reach its primary completion in 2026-10-31. Interventions recorded: IBI3003.
Similar pages
not linked directly; found by shared links- TrialHuman BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM
Shares Multiple myeloma and the tag pipeline.
- TrialStudy of ODX (OsteoDex) in Multiple Myeloma
Shares Multiple myeloma and the tag pipeline.
- TrialA Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
Shares Multiple myeloma and the tag pipeline.
- TrialSARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
Shares Multiple myeloma and the tag pipeline.
- TrialA Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma
Shares Multiple myeloma and the tag pipeline.
- TrialA Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
Shares Multiple myeloma and the tag pipeline.
- TrialA Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma
Shares Multiple myeloma and the tag pipeline.
- TrialAn Open-Label Clinical Study of the Efficacy and Safety of BCD-248 in Patients With Relapsed/Refractory Multiple Myeloma
Shares Multiple myeloma and the tag pipeline.